DIABETOLOGIA is a leading journal in the field of endocrinology and diabetes research, published by Springer since its inception in 1965. With an impactful presence in both Internal Medicine and Endocrinology, Diabetes and Metabolism, it is recognized in the Q1 quartile rankings for 2023, underscoring its significance and contribution to these disciplines. The journal holds impressive Scopus rankings, placing it in the top 5% of journals in its categories, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practices in diabetes care and management. DIABETOLOGIA publishes a range of peer-reviewed articles, original research, and reviews that address the latest scientific developments, clinical practices, and therapeutic innovations, contributing to the global discourse on diabetes and its related health implications. Although it does not offer Open Access options, its rigorous selection process guarantees the quality and relevance of the content, solidifying its position as a reliable reference for contemporary research. For those looking to stay at the forefront of diabetes science, DIABETOLOGIA is a vital communique in the ever-evolving landscape of medical research.

Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.

The Journal of Diabetes and Metabolic Disorders, published by SPRINGER INT PUBL AG, is a premier academic journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. With an E-ISSN of 2251-6581, this journal plays a crucial role in disseminating high-quality research findings from 2012 to 2024, serving as a valuable resource for researchers, practitioners, and students alike. Notably, it has achieved impressive rankings, being placed in the Q2 quartile for Internal Medicine and Q3 for Endocrinology, Diabetes, and Metabolism in 2023, reflecting its influence within the scientific community. The Journal’s commitment to open access ensures that its comprehensive articles, encompassing topics from metabolic disorders to novel therapeutic approaches, are readily available to a global audience. Position yourself at the forefront of medical advancements—contribute to and benefit from the pivotal research presented in this journal.

Canadian Journal of Diabetes is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the understanding and management of diabetes and its associated conditions. Established in 2002, this journal serves as an essential resource for researchers, healthcare professionals, and students interested in the field of endocrinology, diabetes, and metabolism, boasting a commendable Impact Factor that signifies its influence in the academic community. With a focus on high-quality research articles, comprehensive reviews, and insightful commentary, the journal's scope encompasses clinical and experimental studies that address the challenges of diabetes care and prevention. Currently ranked in the Q2 category across multiple relevant categories, including Endocrinology and Medicine, the Canadian Journal of Diabetes is crucial for those seeking to stay at the forefront of diabetes research and practice. The journal is indexed in prestigious databases, making it easily accessible to the global academic community. Located in Amsterdam, Netherlands, it reflects the publisher's commitment to promoting innovation and collaboration in medical research.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

Primary Care Diabetes is a leading journal published by ELSEVIER SCI LTD, focusing on the intersection of diabetes care, endocrinology, and family medicine. Since its inception in 2007, the journal has made significant contributions to the field, achieving notable rankings in various categories, such as Q2 in Endocrinology, Diabetes and Metabolism, Q1 in Family Practice, and Q2 in Internal Medicine, as well as Nutrition and Dietetics for 2023. With an ISSN of 1751-9918 and an E-ISSN of 1878-0210, it serves as an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practice in primary diabetes care. The journal's strong Scopus rankings reflect its commitment to publish high-quality research, fostering clinical practice improvements and enhanced patient outcomes. Although not open access, its articles are pivotal for anyone looking to stay ahead in the dynamic and vital domain of diabetes management.

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.